Literature DB >> 601066

Immune response to myelin basic protein in multiple sclerosis.

R A Hughes, I Gray, R Clifford-Jones, M Stern.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 601066      PMCID: PMC1543539     

Source DB:  PubMed          Journal:  Proc R Soc Med        ISSN: 0035-9157


× No keyword cloud information.
  8 in total

1.  Progressive demyelination and reparative phenomena in chronic experimental allergic encephalomyelitis.

Authors:  D H Snyder; M P Valsamis; S H Stone; C S Raine
Journal:  J Neuropathol Exp Neurol       Date:  1975-05       Impact factor: 3.685

2.  Binding of 125 I myelin basic protein by serum and cerebrospinal fluid.

Authors:  V Lennon; I R Mackay
Journal:  Clin Exp Immunol       Date:  1972-08       Impact factor: 4.330

3.  Search for anti-encephalitogen antibody in human demyelinative diseases.

Authors:  R P Lisak; R G Heinze; G A Falk; M W Kies
Journal:  Neurology       Date:  1968-01       Impact factor: 9.910

4.  Protection of rats from experimental allergic encephalomyelitis with antiserum to guinea-pig spinal cord.

Authors:  R A Hughes
Journal:  Immunology       Date:  1974-04       Impact factor: 7.397

5.  Multiple sclerosis and cell-mediated hypersensitivity to myelin A1 protein.

Authors:  W Sheremata; J B Cosgrove; E H Eylar
Journal:  J Neurol Sci       Date:  1976-04       Impact factor: 3.181

6.  Role of antibodies to galactocerebroside in experimental allergic encephalomyelitis.

Authors:  R A Hughes; S Leibowitz
Journal:  Immunology       Date:  1975-02       Impact factor: 7.397

7.  Radioimmunoassay of myelin basic protein in spinal fluid. An index of active demyelination.

Authors:  S R Cohen; R M Herndon; G M McKhann
Journal:  N Engl J Med       Date:  1976-12-23       Impact factor: 91.245

8.  Radioimmunological determination of myelin basic protein (MBP) and MBP-antibodies.

Authors:  G Schmid; G Thomas; K Hempel; W Grüninger
Journal:  Eur Neurol       Date:  1974       Impact factor: 1.710

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.